<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612298</url>
  </required_header>
  <id_info>
    <org_study_id>DSPC-ALM-1401</org_study_id>
    <nct_id>NCT02612298</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate</brief_title>
  <acronym>ESAHOM</acronym>
  <official_title>Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride
      and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in
      patients with essential hypertension. To provide evidence for hypertension treatment.

      A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol
      succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Compare the efficacy and safety of Arotinolol Hydrochloride and Metoprolol succinate on
      morning blood pressure, heart rate and target organ damage in patients with essential
      hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in diastolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in systolic blood pressure measured by ABPM after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning surge</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in morning surge after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The increase rate of morning blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in the increase rate of morning blood pressure after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning blood pressure (BP) by office BP measure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in morning blood pressure by office BP measure after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate by office BP measure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in heart rate by office BP measure after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity (PWV)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in PWV after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-brachial index (ABI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in ABI after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin-to-creatinine ratio (ACR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in ACR after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate (GFR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in GFR after 12 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety assessed by incidence rate of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>arotinolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arotinolol Hydrochloride</intervention_name>
    <description>Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.</description>
    <arm_group_label>arotinolol</arm_group_label>
    <other_name>Almarl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol succinate sustained-release tablet</intervention_name>
    <description>Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Betaloc tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with systolic blood pressure between 140-179mmHg and/or diastolic blood
             pressure between 90-109mmHg.

          2. Aged between 18-65 years old.

          3. Signed informed consent.

        Exclusion Criteria:

          1. Secondary hypertension

          2. Patients who taking amiodarone over 200mg/day to control arrhythmia

          3. Patients who taking class I antiarrhythmic drugs

          4. Resting heart rate less than 60bpm

          5. Serious liver and kidney disease: aspartate aminotransferase (AST) or alanine
             aminotransferase) (ALT)＞2.5 times upper limit of normal; serum creatinine＞3mg/dl
             (265umol/L)

          6. Severe heart failure: New York Heart Association (NYHA) functional class 2, 3, 4

          7. Myocardial infarction or stroke in the last three months. Unstable angina pectoris in
             the last month.

          8. Patients with asthma or chronic obstructive pulmonary disease.

          9. Pregnancy and breast-feeding

         10. Patients allergy to investigational drugs or have contraindication to investigational
             drugs.

         11. Others unsuitable to participate in the study judged by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yundai Chen, MD</last_name>
    <phone>+86 010 55499209</phone>
    <email>cyundai@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yundai Chen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Yundai Chen, MD</last_name>
      <phone>+86 010 55499209</phone>
      <email>cyundai@medmail.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Essential Hypertension</keyword>
  <keyword>Arotinolol</keyword>
  <keyword>Morning Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Arotinolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

